Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Chinese Subjects With Moderate-to-Severe Atopic Dermatitis

NCT07762833 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT07762833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07762833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Chinese Subjects With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Galderma R&D
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 28, 2026
Completion date
September 28, 2028
Enrollment
240 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis